Your browser doesn't support javascript.
loading
Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer.
Al-Shamsi, Humaid O; Abu-Gheida, Ibrahim; Abdulsamad, Ahmed S; AlAwadhi, Aydah; Alrawi, Sadir; Musallam, Khaled M; Arun, Banu; Ibrahim, Nuhad K.
Afiliação
  • Al-Shamsi HO; Departments of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Abu-Gheida I; Departments of Radiation Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Abdulsamad AS; Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • AlAwadhi A; College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
  • Alrawi S; Departments of Radiation Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Musallam KM; Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Arun B; College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, United Arab Emirates.
  • Ibrahim NK; Department of Oncology, Alzahra Hospital, Dubai, United Arab Emirates.
Oncologist ; 26(11): e2086-e2089, 2021 11.
Article em En | MEDLINE | ID: mdl-34327780
ABSTRACT

BACKGROUND:

The role of somatic mutations in breast cancer prognosis and management continues to be recognized. However, data on the molecular profiles of Arab women are limited. MATERIALS AND

METHODS:

This was a cross-sectional study based on medical chart review of all Arab women diagnosed with breast cancer at a single institution between 2010 and 2018 who underwent next-generation sequencing with Ampliseq 46-Gene or 50-Gene.

RESULTS:

A total of 78 Arab women were identified, with a median age at diagnosis of 52.3 years (range 37-82 years; 38.5% ≤50 years). The majority of patients had stage III or IV disease (74.4%). Next-generation sequencing revealed the following somatic mutation rates TP53, 23.1%; ATM, 2.6%; IDH1, 2.6%; IDH2, 3.8%; PTEN, 7.7%; PIK3CA, 15.4%; APC, 7.7%; NPM1, 2.5%; MPL, 1.3%; JAK2, 2.5%; KIT, 7.7%; KRAS, 3.8%; and NRAS, 3.8%.

CONCLUSION:

Our study illustrates frequencies of somatic mutations in Arab women with breast cancer and suggests potential variations from estimates reported in the Western population. These data calls for larger epidemiologic studies considering the evolving role of such mutations in prognostication and personalized management.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Emirados Árabes Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Oncologist Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Emirados Árabes Unidos